BCG-RIVM versus BCG-Tice versus mitomycin-C in superficial bladder cancer. Rationale, design, and interim analysis of the trial of the South-East Cooperative Urological Group, The Netherlands

Prog Clin Biol Res. 1992:378:59-67.

Authors

W P Witjes¹, P M van der Meijden, E P Roos, J A Witjes, P A Steerenberg, W Doesburg, F M Debruyne

Affiliation

¹ Department of Urology, University of Nijmegen, The Netherlands.

PMID: 1301587

No abstract available

Publication types

Clinical Trial
Comparative Study
Multicenter Study
Randomized Controlled Trial

MeSH terms

Administration, Intravesical
BCG Vaccine / administration & dosage
BCG Vaccine / adverse effects
BCG Vaccine / therapeutic use*
Carcinoma in Situ / drug therapy
Carcinoma in Situ / therapy
Carcinoma, Transitional Cell / drug therapy
Carcinoma, Transitional Cell / therapy
Humans
Mitomycin / administration & dosage
Mitomycin / adverse effects
Mitomycin / therapeutic use*
Neoplasm Recurrence, Local / drug therapy
Neoplasm Recurrence, Local / prevention & control
Neoplasm Recurrence, Local / therapy
Prospective Studies
Urinary Bladder Neoplasms / drug therapy*
Urinary Bladder Neoplasms / therapy*

Substances

BCG Vaccine
Mitomycin